-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
Recently, Beam Therapeutics announced that pre-clinical data proves that cytosine base editor (CBE) has the potential to reduce the expression of viral markers (such as hepatitis B surface antigen HBsAg) and prevent the rebound of hepatitis B virus (HBV)
Chronic hepatitis B is a chronic disease in which the hepatitis B virus continues to be infected for more than 6 months, and the liver undergoes varying degrees of inflammatory necrosis (or) fibrosis
Nucleoside and nucleoside analog drugs currently used to treat hepatitis B can inhibit the hepatitis B virus, but cannot completely remove the virus from the body
Source: Beam Therapeutics' official website
The base editor can directly and irreversibly convert a specific DNA base into another base without causing a double-strand break
Source: Beam Therapeutics' official website
This preclinical in vitro studies designed to evaluate the potential treatment of chronic hepatitis B base editor
Base editing significantly reduces the levels of HBV-related viral markers (HBsAg, HBeAg, HBV DNA, 3.
Source: Beam Therapeutics' official website
These data indicate that CBE can introduce permanent mutations in cccDNA and prevent HBV rebound